By Fineline Cube Sanofi (NASDAQ: SNY) announced the discontinuation of its MOBILIZE phase 3 clinical trial evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment, following an interim analysis that indicated insufficient efficacy.
Trial Status Update
| Item | Detail |
|---|---|
| Company | Sanofi (NASDAQ: SNY) |
| Drug Candidate | Riliprubart (IgG4 humanized monoclonal antibody) |
| Trial Name | MOBILIZE Phase 3 |
| ClinicalTrials.gov ID | NCT06290128 |
| Indication | CIDP refractory to standard-of-care |
| Decision Date | 10 Jun 2026 |
| Reason for Halt | Interim analysis showed unlikely to demonstrate sufficient efficacy |
| Safety Findings | No safety signals identified |
Drug Profile & Mechanism of Action
- Molecule: IgG4 humanized monoclonal antibody
- Target: Activated C1s in the classical complement pathway of the innate immune system
- Mechanism: Selective inhibition of complement activation, a key driver of nerve damage in CIDP
- Development Stage: Phase 3 (MOBILIZE halted; VITALIZE ongoing)
The decision to halt the MOBILIZE trial was based on recommendations from an independent data monitoring committee following a pre-planned interim analysis. While the drug demonstrated a favorable safety profile with no treatment-related safety signals identified, the committee concluded that the study was unlikely to meet its primary efficacy endpoint.
Ongoing Development Program
| Study | Status | Population | ClinicalTrials.gov ID |
|---|---|---|---|
| MOBILIZE | Discontinued | CIDP refractory to standard-of-care | NCT06290128 |
| VITALIZE | Under evaluation | IVIg-treated CIDP patients | NCT06290141 |
Sanofi stated that it will evaluate the implications of the MOBILIZE results for its broader riliprubart development program, including the ongoing VITALIZE phase 3 study in intravenous immunoglobulin (IVIg)-treated CIDP patients.
Market Impact & Outlook
- CIDP Market: Affects approximately 5-7 per 100,000 people globally with limited treatment options
- Therapeutic Gap: Significant unmet need exists for effective treatments in refractory CIDP patients
- Competitive Landscape: Current treatments include IVIg, corticosteroids, and plasma exchange, all with limitations in efficacy, tolerability, or administration burden
- Financial Impact: Sanofi has not disclosed specific financial implications, though R&D expenses for the discontinued trial will be absorbed in Q2 2026 results
- Pipeline Strategy: The company maintains a robust immunology pipeline beyond riliprubart, with multiple assets in mid-to-late stage development
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development decisions, regulatory matters, and future product development. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, and competitive developments.-Fineline Info & Tech